Effectiveness of Rybelsus vs
When will CagriSema be available
RELATED: Novo Nordisk to increase supply of Wegovy after demand-driven supply shortages of starter doses CMS also said that states would be required to cover Wegovy in their Medicaid plans to prevent cardiovascular disease in people with obesity but could also take steps to control usage, such as requiring patients to try other medications or treatments first
Much like managing insulin therapy from a Read More GLP-1 Therapy Discontinuation: How to Identify Patients at Risk and Prevent Drop-Off May 5, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 1,049 views Discontinuation of GLP-1 therapy is becoming a growing concern in diabetes care, even though these treatments show strong clinical benefits
Underlying Health Conditions (e.g., Anemia, Fatigue Disorders) Conditions like pernicious anemia, chronic fatigue, fibromyalgia, or malabsorption issues (e.g., IBS, celiac) often require ongoing support
While overall food intake may be lower on this medication, nutrient intake is even more important to consider